Results 101 to 110 of about 18,836 (198)

Posaconazole-Induced Hypertension and Hypokalemia: Mechanistic Evaluation

open access: yes, 2017
Background Recent studies have shown the new posaconazole delayed-release tablets have superior bioavailability compared with the liquid suspension formulation.
Ian Mchardy   +4 more
core   +1 more source

752. Management of 20 Patients Diagnosed with Posaconazole-Induced Pseudohyperaldosteronism [PDF]

open access: yes, 2020
Background Posaconazole-induced pseudohyperaldosteronism (PIPH) has been associated with elevated posaconazole serum concentrations. Clinicians are faced with the difficult task of managing patients with PIPH while not compromising the efficacy of ...
Nguyen, Minh-Vu   +5 more
core  

Prevention of invasive fungal infections in immunocompromised patients: the role of delayed-release posaconazole

open access: yesInfection and Drug Resistance, 2015
Ahmet SoysalDivision of Pediatric Infectious Diseases, Department of Pediatrics, Faculty of Medicine, Marmara University, Istanbul, TurkeyAbstract: Posaconazole is a triazole antifungal agent that has broad-spectrum activity against many yeasts and ...
Soysal A
doaj  

Posaconazole with Combination Salvage Treatment in Pediatric Immunocompromised Patients

open access: yes, 2018
Objective: Posaconazole is a recently developed wide-spectrum antifungal medication for which insufficient data is available regarding its potential pediatric use as a salvage therapy for systemic fungal infections in Turkey.
Akturk, Hacer   +7 more
core   +1 more source

Establishment and Validation of a UPLC-MS/MS Method for Quantitative Determination of Zanubrutinib and Posaconazole in Rat Plasma: Application in Drug–Drug Interaction Studies

open access: yesDrug Design, Development and Therapy
Hailun Xia,1 Yuxin Shen,1,2 Xinhao Xu,1,2 Jun Wu,1,2 Guanyang Lin,1,2 Xiaoxiang Du1 1Department of Pharmacy, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, People’s Republic of China; 2School of Pharmaceutical Sciences ...
Xia H, Shen Y, Xu X, Wu J, Lin G, Du X
doaj  

Factors affecting posaconazole plasma concentrations: a meta-analysis and systematic review

open access: yesFrontiers in Pharmacology
BackgroundPosaconazole is a potent antifungal agent widely used to manage invasive fungal infections, especially in immunocompromised individuals.
Ruochen Qu   +11 more
doaj   +1 more source

732. Posaconazole Serum Drug Levels Associated with Pseudohyperaldosteronism [PDF]

open access: yes, 2019
Background Posaconazole is an extended-spectrum triazole used in the treatment and prophylaxis of many fungal diseases. There have been case reports of posaconazole-induced pseudohyperaldosteronism; however, its occurrence and association with serum ...
Nguyen, Minh-Vu   +7 more
core  

Posaconazole: The case for therapeutic drug monitoring

open access: yes, 2012
Invasive fungal infections are associated with high morbidity and mortality. Antifungal therapeutic options remain relatively limited; therefore, optimization of present regimens is essential.
Felton, Timothy W.; id_orcid   +3 more
core   +1 more source

Posaconazole as rescue therapy in African histoplasmosis

open access: yesBrazilian Journal of Infectious Diseases, 2013
Posaconazole Histoplasmosis Salvage therapy African histoplasmosis is a granulomatous mycosis caused by Histoplasma capsulatum var. duboisii. Treatment is usually extrapolated from guidelines for classical histoplasmosis, and includes 2-4 weeks of ...
Daniel Gonçalves   +2 more
doaj  

Posaconazole-Loaded Chitosan Transdermal Films: A Microemulsion-Based Strategy for Aspergillosis [PDF]

open access: yes
Posaconazole, a broad-spectrum antifungal agent, has gained prominence in the treatment of Aspergillosis. However, its clinical efficacy is often limited due to poor bioavailability and the need for frequent administration. To overcome these limitations,
Subham Mandal, Suraj Mandal
core   +1 more source

Home - About - Disclaimer - Privacy